Last reviewed · How we verify

NCT05138562

TUC3PII-01_TU2670 Phase IIa Clinical Study

Completed Phase 2 Last updated 13 August 2024
What this trial tests

Phase 2 trial testing Placebo Comparator: Placebo in Endometriosis in 86 participants. Completed in 5 August 2024.

Timeline
19 August 2021
Primary endpoint
23 January 2024
5 August 2024

Quick facts

Lead sponsorTiumBio Co., Ltd.
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment86
Start date19 August 2021
Primary completion23 January 2024
Estimated completion5 August 2024
Sites40 locations across Italy, Russia, Ukraine, Poland, Czechia

Drugs / interventions tested

Conditions studied

Sponsor

TiumBio Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other TiumBio Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05138562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing